Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Generated: April 23, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 076135

« Back to Dashboard

NDA 076135 describes CLARAVIS, which is a drug marketed by Teva Pharms Usa and is included in two NDAs. It is available from one supplier. Additional details are available on the CLARAVIS profile page.

The generic ingredient in CLARAVIS is isotretinoin. There are eleven drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the isotretinoin profile page.

Summary for 076135

Tradename:	CLARAVIS
Applicant:	Teva Pharms Usa
Ingredient:	isotretinoin
Patents:	0
Therapeutic Class:	Dermatological Agents
Formulation / Manufacturing:	see details

Pharmacology for NDA: 076135

Ingredient-type	Retinoids

Medical Subject Heading (MeSH) Categories for 076135

Dermatologic Agents
Teratogens

Suppliers and Packaging for NDA: 076135

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
CLARAVIS	isotretinoin	CAPSULE;ORAL	076135	ANDA	Teva Pharmaceuticals USA, Inc.	0555-1055	N	0555-1055-86
CLARAVIS	isotretinoin	CAPSULE;ORAL	076135	ANDA	Teva Pharmaceuticals USA, Inc.	0555-1055	N	0555-1055-56

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	CAPSULE;ORAL			Strength	40MG
Approval Date:	Apr 11, 2003	TE:	AB	RLD:	No

Profile for product number 002

Active Rx/OTC/Discontinued:	RX	Dosage:	CAPSULE;ORAL			Strength	20MG
Approval Date:	Apr 11, 2003	TE:	AB	RLD:	No

Profile for product number 003

Active Rx/OTC/Discontinued:	RX	Dosage:	CAPSULE;ORAL			Strength	30MG
Approval Date:	May 11, 2006	TE:	AB	RLD:	No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington

Chubb

Medtronic

Teva

Harvard Business School

Johnson and Johnson

Fuji

Mallinckrodt

Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.